Cerevance

 ICYMI, we had a great time contributing to the discussion on precision neurotherapeutics during the 2024 BIO International Convention. It’s always enriching to engage with industry peers to brainstorm innovative approaches to better serve patient needs.

Precision Psychiatry Spotlight at #BIO2024: Our CEO, Craig Thompson, will discuss impressive strides in the field of #PrecisionPsychiatry with Susanne Ahmari, MD, Assistant Professor, Department of Psychiatry, University of Pittsburgh, Amit Etkin, MD, Founder and CEO, Alto Neuroscience, and UPMC Enterprises’ senior advisor & CEO of Generian, Hank Safferstein, PhD. https://lnkd.in/e3RTzu4v

ICYMI, our team presented a poster at #SLASEurope2024 this past week highlighting the capabilities of our NETSseq platform and our innovative work in the #CNS space for #neurodegenerativediseases, such as Alzheimer’s.

What an exciting achievement and meaningful progress for patients and families affected by Parkinson's disease. The team at Cerevance is dedicated to advancing innovation in PD therapeutics and this bill brings our industry another step closer. https://lnkd.in/ej_uUxfS

In observance of #ALSAwarenessMonth, did you know that someone is diagnosed with ALS every 90 minutes? Our commitment lies in the pursuit of a safe and effective treatment for ALS. This dedication drives our efforts to advance our novel therapy, CVN293, which aims at slowing neurodegeneration. Learn more here: https://bit.ly/4afoFbI

We look forward to participating in an upcoming panel discussion during the BIO International Convention on Tuesday, June 4th at 11 a.m. PT, titled, "Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics." Join us to learn more about how the industry is innovating on behalf of individuals with brain diseases. https://lnkd.in/eCuaKvJm

We are delighted that Cerevance has been recognized by the Cambridge Independent Science & Technology Awards for its ongoing contributions to the life sciences community for the second year in a row! 

We’re headed to Lisbon for the #IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders. Dr. Karl Kieburtz will present findings from our Phase 2 study of CVN424. Learn more here: https://lnkd.in/eDvXiJ3 #parkinson’s #conference #clinical #research

The Drug Hunter recognized CVN293, a KCNK13 inhibitor with potential applications in treating multiple CNS disorders, as one of April’s Molecules of the Month!

Amyotrophic Lateral Sclerosis (#ALS) is a neurodegenerative condition that weakens motor nerve cells responsible for movements like walking, swallowing, and ultimately, breathing. There are 5,000 new cases each year and currently, no known cure. We’re inspired by The ALS Association’s leadership in ALS research, care, education, and advocacy. This #ALSAwarenessMonth, learn more about the incredible work they do: https://www.als.org/ #cns #awareness #disease #neuroscience